This clinical trial is focused on studying a type of cancer called diffuse large B-cell lymphoma (DLBCL), which is a common form of non-Hodgkin lymphoma. The study is specifically looking at patients who have been newly diagnosed with high-intermediate and high-risk DLBCL. The trial aims to compare the effectiveness and safety of a new treatment combination that includes tafasitamab and lenalidomide along with a standard treatment regimen known as R-CHOP, against the standard R-CHOP treatment alone. R-CHOP is a combination of drugs used to treat lymphoma, including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
The study will involve participants receiving either the new treatment combination or the standard treatment. Some participants will receive a placebo instead of the new drugs to help compare the results. The trial will monitor the participants over a period to see how well the cancer responds to the treatments and to check for any side effects. The goal is to determine if the new combination of tafasitamab and lenalidomide with R-CHOP is more effective than R-CHOP alone in treating DLBCL.
Participants in the trial will undergo regular assessments to track their health and the progress of their treatment. These assessments will include various tests and evaluations to ensure the safety and effectiveness of the treatment. The study is expected to continue until 2026, providing valuable information on the potential benefits of the new treatment combination for patients with DLBCL.
1joining the study
Upon joining the study, the patient will be randomly assigned to one of two groups. One group will receive the standard treatment known as R-CHOP, while the other group will receive R-CHOP plus additional medications, tafasitamab and lenalidomide.
2treatment phase
The treatment phase involves a combination of medications administered over several cycles. Each cycle lasts 21 days.
The standard R-CHOP treatment includes the following medications: rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisone. These are given through intravenous use or orally, depending on the specific medication.
For patients in the experimental group, tafasitamab is administered intravenously, and lenalidomide is taken orally. The dosage and frequency are determined by the study protocol.
3monitoring and assessments
Throughout the treatment phase, regular monitoring and assessments are conducted to evaluate the patient’s response to the treatment. This includes imaging tests and blood tests.
The primary goal is to assess progression-free survival, which measures the time during and after treatment that the patient lives without the disease worsening.
4end of treatment evaluation
At the end of the treatment phase, a comprehensive evaluation is performed to determine the overall response to the therapy.
This includes assessing the complete response rate, which indicates the absence of detectable cancer following treatment.
5follow-up period
After completing the treatment, patients enter a follow-up period where they are monitored for any long-term effects and overall survival.
The follow-up includes regular check-ups and assessments to ensure the patient’s health and to detect any recurrence of the disease.
Who Can Join the Study?
Sign a written informed consent form, which means you agree to participate in the study after understanding all the details.
Have certain blood test results at the start of the study, including:
Absolute neutrophil count (a type of white blood cell) of at least 1.5 x 109/L, unless affected by the disease.
Platelet count (cells that help with blood clotting) of at least 75 x 109/L, unless affected by the disease.
Total serum bilirubin (a substance made by the liver) less than 1.5 times the normal limit, unless you have a specific condition like Gilbert’s Syndrome or liver involvement by lymphoma.
ALT, AST, and ALP (liver enzymes) less than 3 times the normal limit, or less than 5 times if the liver is involved.
Serum creatinine clearance (a measure of kidney function) of at least 30 mL/minute.
Be able and willing to take medication to prevent blood clots, such as aspirin or a type of blood thinner, if needed.
Understand and agree to follow all study procedures and instructions.
Not have a history of not following medical instructions or being unreliable.
Understand and agree to follow special conditions to prevent pregnancy if applicable.
If you are a woman who can have children, you must:
Not be pregnant, confirmed by tests.
Agree not to breastfeed or donate eggs during the study and for three months after.
Agree to regular pregnancy testing and counseling if needed.
Agree to avoid pregnancy by using effective birth control or abstaining from sex.
If you are a male participant, you must:
Use effective birth control if sexually active with a woman who can have children.
Not donate sperm during the study and for three months after.
Be between 18 and 80 years old.
Have not received previous treatment for the specific type of lymphoma being studied.
Provide a sample of tumor tissue for review, either from a previous biopsy or a new one.
Have certain measurable areas of disease that can be tracked during the study.
Have a performance status of 0, 1, or 2, which means you are able to carry out daily activities with varying degrees of help.
Have a specific score on a scale that assesses the risk of the disease, depending on your age.
Start treatment within 28 days of being diagnosed with the disease.
Have a heart function test showing a left ventricular ejection fraction of at least 50%.
Who Cannot Join the Study?
Patients who have not been newly diagnosed with high-intermediate or high-risk diffuse large B-cell lymphoma (DLBCL) cannot participate.
Patients who are not within the specified age range for the study cannot participate.
Patients who do not meet the gender requirements for the study cannot participate.
Patients who are considered part of a vulnerable population, which means they might need special protection or care, cannot participate.
Tafasitamab is a medication used in this trial to treat patients with diffuse large B-cell lymphoma (DLBCL). It is designed to target and destroy specific cancer cells, helping to reduce the size of tumors and slow the progression of the disease.
Lenalidomide is another medication included in the trial. It works by affecting the immune system to help fight cancer cells. It can also inhibit the growth of new blood vessels that tumors need to grow.
R-CHOP is a combination of several chemotherapy drugs used to treat lymphoma. It includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. This combination works together to kill cancer cells and reduce the size of tumors.
Diffuse Large B-Cell Lymphoma (DLBCL) – This is a type of non-Hodgkin lymphoma that originates in the B-cells, which are a type of white blood cell responsible for producing antibodies. It is characterized by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow, or other organs. The disease often presents with symptoms such as swollen lymph nodes, fever, night sweats, and weight loss. DLBCL can progress quickly, requiring prompt medical attention. It is classified as high-intermediate and high-risk based on certain clinical and biological factors. The progression of the disease is typically monitored using criteria such as the Lugano Response Criteria for Malignant Lymphoma.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Czechia 
France 
Germany 
Hungary 
Ireland 
Italy 
Poland 
Romania 
Slovakia 
Spain 